Ajanta de, MD
Interventional Cardiology · Burlingame, CANPI 1336198878
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Terumo Medical Corporation at 35.6% of the total. Reporting peaked in 2019 at $3,954 and has fallen 50.9% since, to $1,940 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.
Across 151 payments — averaging $65.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Terumo Medical Corporation$4K
- Abbott$2K
- Medical Device Business Services, Inc.$1K
- Organogenesis Inc.$472
- Johnson & Johnson$364
- Abiomed$294
- plus $2K from 20 others
Across 47 payments — averaging $2172.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endologix LLC$60K
- Medtronic$43K
What the payments were for
- Consulting fees$3,50036%
- Travel & lodging$2,47725%
- Food & beverage$3,86739%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Terumo Medical Corporation | 2 | $3,500 |
| Abbott | 37 | $2,392 |
| Medical Device Business Services, Inc. | 9 | $1,194 |
| Organogenesis Inc. | 11 | $472 |
| Johnson & Johnson | 26 | $364 |
| Abiomed | 2 | $294 |
| Medtronic(2 entities) | 21 | $252 |
| Amgen | 7 | $182 |
| Integra Lifesciences Corporation | 1 | $145 |
| Bardy Diagnostics, Inc. | 6 | $145 |
| Biosense Webster, Inc. | 1 | $139 |
| Baxter Healthcare | 4 | $97 |
| Smith+Nephew | 3 | $95 |
| Endologix LLC | 1 | $94 |
| Esperion Therapeutics, Inc. | 3 | $74 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| AstraZeneca | 3 | $57 |
| Bard Peripheral Vascular, Inc. | 1 | $52 |
| Astellas Pharma US Inc | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $43 |
| Sirtex Medical Inc | 1 | $38 |
| Angiodynamics, Inc. | 1 | $26 |
| Biotronik Inc. | 1 | $23 |
| Pfizer | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRICLIP$1,212
- Carto 3$1,118
- INTEGRA$436
- PuraPly$256
- INTEGRA DERMAL REGENERATION TEMPLATE$145
- PRIMATRIX$145
- Diamondback Coronary$125
- Mitra Clip system$105
How this compares
$9,843 in reported general payments places this provider in the 50th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $186,514 |
| EntrestoSacubitril/Valsartan | 47 | $52,758 |
| XareltoRivaroxaban | 23 | $38,402 |
| Repatha SureclickEvolocumab | 22 | $21,305 |
| ClopidogrelClopidogrel Bisulfate | 288 | $3,987 |
| Atorvastatin Calcium | 317 | $3,140 |
| Metoprolol Succinate | 201 | $2,869 |
| Flecainide Acetate | 62 | $2,251 |
| Rosuvastatin Calcium | 115 | $1,627 |
| Ezetimibe | 63 | $1,410 |
| Pantoprazole Sodium | 86 | $1,301 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 58 | $1,262 |
| Carvedilol | 93 | $1,024 |
| Amlodipine Besylate | 105 | $1,005 |
| Lisinopril | 136 | $987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $186,514137 claims |
| Johnson & JohnsonXarelto | $364 | $38,40223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Burlingame
- Christian SpiesBurlingame$719K
- David DanielsBurlingame$319K
- Ning NingBurlingame$124K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.